Sonye K Danoff

List of Publications by Year
in descending order

94 papers	8,322 citations	108046 37 h-index	62345 84 g-index
96 all docs	96 docs citations	96 times ranked	7340 citing authors

#	Article	IF	Citations
1	<scp>Antiâ€Cortactin</scp> Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis. Arthritis and Rheumatology, 2022, 74, 358-364.	2.9	6
2	Performance of the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Idiopathic Inflammatory Myopathies in Patients With <scp>Myositisâ€Specific</scp> Autoantibodies. Arthritis and Rheumatology, 2022, 74, 508-517.	2.9	24
3	Assessing predictors of rheumatoid arthritis-associated interstitial lung disease using quantitative lung densitometry. Rheumatology, 2022, 61, 2792-2804.	0.9	7
4	Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases. Respirology, 2022, 27, 294-300.	1.3	15
5	Provider Perspectives on and Access to Palliative Care for Patients With Interstitial Lung Disease. Chest, 2022, 162, 375-384.	0.4	6
6	The telemedicine experience: using principles of clinical excellence to identify disparities and optimize care. Medicine (United States), 2022, 101, e29017.	0.4	4
7	Impact of Sex and Gender on Autoimmune Lung Disease: Opportunities for Future Research: NHLBI Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 817-823.	2.5	3
8	Nodules, Adenopathy, and a Unilateral Opacity Mistaken for Granulomatous Disease. American Journal of Medicine, 2021, 134, e333-e334.	0.6	1
9	A North American Cohort of Antiâ€SAE Dermatomyositis: Clinical Phenotype, Testing, and Review of Cases. ACR Open Rheumatology, 2021, 3, 287-294.	0.9	28
10	Providing Patient-Centered Care in Interstitial Lung Disease. Clinics in Chest Medicine, 2021, 42, 337-346.	0.8	3
11	Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2021, 204, e3-e23.	2.5	41
12	The phenotype of myositis patients with anti-Ku autoantibodies. Seminars in Arthritis and Rheumatism, 2021, 51, 728-734.	1.6	13
13	A scoping review of palliative care outcome measures in interstitial lung disease. European Respiratory Review, 2021, 30, 210080.	3.0	2
14	Burden and Unmet Needs with Portable Oxygen in Patients on Long-Term Oxygen Therapy. Annals of the American Thoracic Society, 2021, 18, 1498-1505.	1.5	8
15	Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC. JTO Clinical and Research Reports, 2021, 2, 100220.	0.6	4
16	The Role of Surgical Lung Biopsy in the Diagnosis of Fibrotic Interstitial Lung Disease: Perspective from the Pulmonary Fibrosis Foundation. Annals of the American Thoracic Society, 2021, 18, 1601-1609.	1.5	8
17	ACR Appropriateness CriteriaÂ® Diffuse Lung Disease. Journal of the American College of Radiology, 2021, 18, S320-S329.	0.9	2
18	Myositis Autoantibodies: A Comparison of Results From the Oklahoma Medical Research Foundation Myositis Panel to the Euroimmun Research Line Blot. Arthritis and Rheumatology, 2020, 72, 192-194.	2.9	34

#	Article	IF	Citations
19	Transbronchial Cryobiopsy for the Diagnosis of Interstitial Lung Diseases. Chest, 2020, 157, 1030-1042.	0.4	134
20	Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e36-e69.	2.5	508
21	Chronic immune checkpoint inhibitor pneumonitis. , 2020, 8, e000840.		55
22	Predictors of progression in systemic sclerosis patients with interstitial lung disease. European Respiratory Journal, 2020, 55, 1902026.	3.1	134
23	Pneumocystis jirovecii Pneumonia and Other Infections in Idiopathic Inflammatory Myositis. Current Rheumatology Reports, 2020, 22, 7.	2.1	5
24	Clinical Features of Myositis: Lung Manifestations. , 2020, , 57-62.		0
25	Myositis-Associated Interstitial Lung Disease. , 2020, , 247-256.		0
26	Interstitial Lung Disease in Polymyositis and Dermatomyositis. Clinics in Chest Medicine, 2019, 40, 561-572.	0.8	72
27	Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease. Chest, 2019, 156, 896-906.	0.4	77
28	More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies. Neurology, 2019, 93, e1768-e1777.	1.5	35
29	The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Advances in Therapy, 2019, 36, 3279-3287.	1.3	45
30	Collecting patient preference information using a Clinical Data Research Network: demonstrating feasibility with idiopathic pulmonary fibrosis . Patient Preference and Adherence, 2019, Volume 13, 795-804.	0.8	2
31	Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies. Neurology, 2019, 92, e1416-e1426.	1.5	36
32	COUNTERPOINT: Does Interstitial Pneumonia With Autoimmune Features Represent a Distinct Class of Patients With Idiopathic Interstitial Pneumonia? No. Chest, 2019, 155, 260-263.	0.4	9
33	Rebuttal From Drs Oldham and Danoff. Chest, 2019, 155, 264-265.	0.4	0
34	Sonographic findings from inflammatory arthritis due to antisynthetase syndrome. Clinical Rheumatology, 2019, 38, 1477-1483.	1.0	8
35	Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. Journal of Thoracic Oncology, 2019, 14, 494-502.	0.5	114
36	The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. Journal of Clinical Investigation, 2019, 129, 4305-4315.	3.9	100

#	Article	IF	Citations
37	Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome. Clinical and Experimental Rheumatology, 2019, 37, 858-861.	0.4	5
38	Prognostic factors in 'pneumo-myositis'. Nature Reviews Rheumatology, 2018, 14, 253-254.	3.5	1
39	The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis. Seminars in Arthritis and Rheumatism, 2018, 48, 504-512.	1.6	36
40	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1036-1044.	2.5	174
41	Nonpharmacologic Therapy for Idiopathic Pulmonary Fibrosis. , 2018, , 65-74.		0
42	Risk factors for mortality and mortality rates in interstitial lung disease patients in the intensive care unit. European Respiratory Review, 2018, 27, 180061.	3.0	27
43	Treatment of Interstitial Lung Disease Associated With Myositis and the Anti-Synthetase Syndrome. Current Treatment Options in Rheumatology, 2018, 4, 316-328.	0.6	1
44	Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis. Frontiers in Immunology, 2018, 9, 2696.	2.2	34
45	Pneumonitis in Nonâ€“Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. Journal of Thoracic Oncology, 2018, 13, 1930-1939.	0.5	282
46	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e44-e68.	2.5	2,678
47	Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies. Neurology, 2018, 90, e2068-e2076.	1.5	76
48	Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle. Arthritis Care and Research, 2017, 69, 263-270.	1.5	108
49	Toward understanding patient experience in idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 49, 1602202.	3.1	1
50	Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients. Arthritis Care and Research, 2017, 69, 1771-1776.	1.5	130
51	Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Annals of the Rheumatic Diseases, 2017, 76, 681-687.	0.5	132
52	â€œHikerâ€™s feetâ€ a novel cutaneous finding in the inflammatory myopathies. Clinical Rheumatology, 2017, 36, 1683-1686.	1.0	36
53	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1249-1254.	2.5	166
54	A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology, 2017, 56, 999-1007.	0.9	166

#	Article	IF	Citations
55	Exploration of the MUC5B promoter variant and ILD risk in patients with autoimmune myositis. Respiratory Medicine, 2017, 130, 52-54.	1.3	22
56	Smoking and Subclinical ILD in RA versus the Multi-Ethnic Study of Atherosclerosis. PLoS ONE, 2016, 11, e0153024.	1.1	19
57	Statin-Induced Anti-HMGCR-Associated Myopathy. Journal of the American College of Cardiology, 2016, 68, 234-235.	1.2	44
58	Intravenous Immunoglobulin as Potential Adjunct Therapy for Interstitial Lung Disease. Annals of the American Thoracic Society, 2016, 13, 1682-1688.	1.5	21
59	Symptomâ€based management of the idiopathic interstitial pneumonia. Respirology, 2016, 21, 1357-1365.	1.3	25
60	Cytosolic 5â€²â€Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases. Arthritis Care and Research, 2016, 68, 66-71.	1.5	89
61	Management of interstitial lung disease associated with connective tissue disease. BMJ, The, 2016, 352, h6819.	3.0	217
62	Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient. Chest, 2015, 148, 242-252.	0.4	36
63	The Genetics of Pulmonary Fibrosis. , 2014, , 207-220.		0
64	Pulmonary Manifestations of Polymyositis/Dermatomyositis. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 239-248.	0.8	70
65	Lung transplantation in telomerase mutation carriers with pulmonary fibrosis. European Respiratory Journal, 2014, 44, 178-187.	3.1	161
66	Interstitial lung disease associated with the idiopathic inflammatory myopathies and the antisynthetase syndrome. Current Opinion in Rheumatology, 2014, 26, 684-689.	2.0	51
67	Association of fine specificity and repertoire expansion of anticitrullinated peptide antibodies with rheumatoid arthritis associated interstitial lung disease. Annals of the Rheumatic Diseases, 2014, 73, 1487-1494.	0.5	140
68	A Roadmap to Promote Clinical and Translational Research in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Chest, 2014, 145, 454-463.	0.4	67
69	Inflammatory Myopathy/Anti synthetase Syndrome. , 2014, , 49-59.		0
70	Pulmonary Manifestations of SjÃ¶grenâ€™s Syndrome. Current Allergy and Asthma Reports, 2013, 13, 354-360.	2.4	60
71	Antiâ€“Melanoma Differentiationâ€“Associated Protein 5â€“Associated Dermatomyositis: Expanding the Clinical Spectrum. Arthritis Care and Research, 2013, 65, 1307-1315.	1.5	241
72	Role of support measures and palliative care. Current Opinion in Pulmonary Medicine, 2013, 19, 480-484.	1.2	26

#	Article	IF	Citations
73	Thalidomide Suppresses Cough And Improves Quality Of Life In Patients With Idiopathic Pulmonary Fibrosis. , 2012, , .		0
74	Thalidomide for the Treatment of Cough in Idiopathic Pulmonary Fibrosis. Annals of Internal Medicine, 2012, 157, 398.	2.0	179
75	Bronchiolitis. Immunology and Allergy Clinics of North America, 2012, 32, 601-619.	0.7	12
76	Exacerbations in Idiopathic Pulmonary Fibrosis Triggered by Pulmonary and Nonpulmonary Surgery: A Case Series and Comprehensive Review of the Literature. Lung, 2012, 190, 373-380.	1.4	86
77	The lung as a possible target for the immune reaction in myositis. Arthritis Research and Therapy, 2011, 13, 230.	1.6	20
78	Interstitial Lung Disease in Idiopathic Inflammatory Myopathy. Current Rheumatology Reviews, 2010, 6, 108-119.	0.4	77
79	Expression of the transcription factor, TFII-I, during post-implantation mouse embryonic development. BMC Research Notes, 2010, 3, 203.	0.6	6
80	VEGF As A Marker Of Interstitial Fibrosis In Patients With Rheumatoid Arthritis. , 2010, , .		0
81	Antisynthetase Syndrome: Comparison Of Laboratory And Clinical Characteristics Of Muscle And Lung In Jo1 Vs. Non-Jo1 Patients. , 2010, , .		0
82	Interstitial Lung Disease Associated With the Idiopathic Inflammatory Myopathies. Chest, 2010, 138, 1464-1474.	0.4	366
83	Respiratory symptoms and disease characteristics as predictors of pulmonary function abnormalities in patients with rheumatoid arthritis: an observational cohort study. Arthritis Research and Therapy, 2010, 12, R104.	1.6	38
84	Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respiratory Medicine, 2009, 103, 1152-1158.	1.3	116
85	Interstitial lung disease and sleep: What is known?. Sleep Medicine, 2009, 10, 947-951.	0.8	29
86	Clinical Profile of Anti-PL-12 Autoantibody. Chest, 2009, 135, 1550-1556.	0.4	145
87	Sleep Quality and Health-Related Quality of Life in Idiopathic Pulmonary Fibrosis. Chest, 2008, 134, 693-698.	0.4	84
88	A ClinicianÊ¼s Guide to the Diagnosis and Treatment of Interstitial Lung Diseases. Southern Medical Journal, 2007, 100, 579-587.	0.3	12
89	Vascular Endothelial Growth Factor Receptor-2. Journal of Biological Chemistry, 2005, 280, 29856-29863.	1.6	32
90	Pleuropulmonary Disease Due to Pergolide Use for Restless Legs Syndrome. Chest, 2001, 120, 313-316.	0.4	72

#	Article	IF	Citations
91	The inositol trisphosphate receptor gene family: Implications for normal and abnormal brain function. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1994, 18, 1-16.	2.5	10
92	Inositol (1,4,5)-trisphosphate receptor: characterization of neuron-specific alternative splicing in rat brain and peripheral tissues. Molecular Brain Research, 1993, 17, 212-216.	2.5	19
93	Tethered IP3. Synthesis and biochemical applications of the 1-O-(3-aminopropyl) ester of inositol (1,4,5)-trisphosphate. Journal of the American Chemical Society, 1991, 113, 1822-1825.	6.6	72
94	Is histamine potentiation ofadenosine-stimulated cyclic AMP accumulation in guinea-pig cerebral cortical slices mediated by products of inositol phospholipid breakdown?. Biochemical Pharmacology, 1987, 36, 1177-1179.	2.0	13